Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells

Clinical studies evaluating targeted BRAFV600E inhibitors in advanced thyroid cancer patients are currently underway. Vemurafenib (BRAFV600E inhibitor) monotherapy has shown promising results thus far, although development of resistance is a clinical challenge. The objective of this study was to cha...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Hanly, Elyse K., Tuli, Neha Y., Bednarczyk, Robert B., Suriano, Robert, Geliebter, Jan, Moscatello, Augustine L., Darzynkiewicz, Zbigniew, Tiwari, Raj K.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2015
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4890996/
https://ncbi.nlm.nih.gov/pubmed/26735176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6779
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items